Structure-based discovery of a new protein-aggregation breaking excipient

Area of Science:

• Biochemistry
• Pharmaceutical Sciences
• Protein Engineering

Background:

• Protein aggregation reduces therapeutic protein activity and can trigger adverse immune responses.
• The biopharmaceutical industry requires stable, high-concentration formulations, often without refrigeration.
• Formulation stability is limited by pH, ionic strength, and a few excipients.

Purpose of the Study:

• To develop a structure-based computational approach for discovering novel anti-aggregation molecules.
• To identify excipients that can effectively prevent protein aggregation in high-concentration formulations.
• To apply this approach to a model therapeutic protein, Interferon-alpha-2a.

Main Methods:

• Utilized a structure-based computational strategy to screen for potential anti-aggregation molecules.
• Applied the developed approach to the specific case of Interferon-alpha-2a.
• Evaluated the efficacy of identified molecules in reducing protein aggregation.

Main Results:

• Successfully identified novel molecules capable of reducing protein aggregation.
• Demonstrated the applicability of the structure-based approach for protein formulation development.
• Provided insights into the mechanism of aggregation inhibition for Interferon-alpha-2a.

Conclusions:

• A structure-based approach is effective for discovering new anti-aggregation molecules.
• This method aids in developing stable, high-concentration protein formulations.
• The findings support the advancement of biopharmaceutical product development and patient safety.